151 related articles for article (PubMed ID: 33452612)
41. A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
Guo J; Yang J; Zhang X; Feng X; Zhang H; Chen L; Johnson H; Persson JL; Xiao K
Anticancer Res; 2018 Mar; 38(3):1471-1477. PubMed ID: 29491074
[TBL] [Abstract][Full Text] [Related]
42. A peptide-centric approach to analyse quantitative proteomics data- an application to prostate cancer biomarker discovery.
Lima T; Rodrigues JE; Manadas B; Henrique R; Fardilha M; Vitorino R
J Proteomics; 2023 Feb; 272():104774. PubMed ID: 36427804
[TBL] [Abstract][Full Text] [Related]
43. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
44. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
Minnee P; Hessels D; Schalken JA; Van Criekinge W
BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
[TBL] [Abstract][Full Text] [Related]
45. Urinary biomarkers of prostate cancer.
Fujita K; Nonomura N
Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
[TBL] [Abstract][Full Text] [Related]
46. Urinary Biomarkers for Prostate Cancer.
Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
[TBL] [Abstract][Full Text] [Related]
47. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
[TBL] [Abstract][Full Text] [Related]
48. Urinary proteomic profiles of prostate cancer with different risk of progression and correlation with histopathological features.
Bergamini S; Caramaschi S; Monari E; Martorana E; Salviato T; Mangogna A; Balduit A; Tomasi A; Canu P; Bellei E
Ann Diagn Pathol; 2021 Apr; 51():151704. PubMed ID: 33460996
[TBL] [Abstract][Full Text] [Related]
49. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
50. Identification of prostate cancer biomarkers in urinary exosomes.
Øverbye A; Skotland T; Koehler CJ; Thiede B; Seierstad T; Berge V; Sandvig K; Llorente A
Oncotarget; 2015 Oct; 6(30):30357-76. PubMed ID: 26196085
[TBL] [Abstract][Full Text] [Related]
51. Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile.
Vermassen T; D'Herde K; Jacobus D; Van Praet C; Poelaert F; Lumen N; Callewaert N; Decaestecker K; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
J Clin Pathol; 2017 Oct; 70(10):838-846. PubMed ID: 28360190
[TBL] [Abstract][Full Text] [Related]
52. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
53. Detection of Core2 β-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer.
Kojima Y; Yoneyama T; Hatakeyama S; Mikami J; Sato T; Mori K; Hashimoto Y; Koie T; Ohyama C; Fukuda M; Tobisawa Y
PLoS One; 2015; 10(9):e0138520. PubMed ID: 26390303
[TBL] [Abstract][Full Text] [Related]
54. Urinary thiosulfate as failed prostate cancer biomarker - an exemplary multicenter re-evaluation study.
Stephan C; Wilkosz J; Różański W; Ecke TH; Lein M; Bryś M; Krześlak A; Chwatko G; Jung K
Clin Chem Lab Med; 2015 Feb; 53(3):477-83. PubMed ID: 25274944
[TBL] [Abstract][Full Text] [Related]
55. Identification of the PCA29 gene signature as a predictor in prostate cancer.
Lee JY; Lin SY; Lin CY; Chuang YH; Huang SH; Tseng YY; Wang HJ; Yang JM
J Bioinform Comput Biol; 2019 Jun; 17(3):1940006. PubMed ID: 31288639
[TBL] [Abstract][Full Text] [Related]
56. Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer.
Royo F; Zuñiga-Garcia P; Torrano V; Loizaga A; Sanchez-Mosquera P; Ugalde-Olano A; González E; Cortazar AR; Palomo L; Fernández-Ruiz S; Lacasa-Viscasillas I; Berdasco M; Sutherland JD; Barrio R; Zabala-Letona A; Martín-Martín N; Arruabarrena-Aristorena A; Valcarcel-Jimenez L; Caro-Maldonado A; Gonzalez-Tampan J; Cachi-Fuentes G; Esteller M; Aransay AM; Unda M; Falcón-Pérez JM; Carracedo A
Oncotarget; 2016 Feb; 7(6):6835-46. PubMed ID: 26771841
[TBL] [Abstract][Full Text] [Related]
57. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
Whitaker HC; Kote-Jarai Z; Ross-Adams H; Warren AY; Burge J; George A; Bancroft E; Jhavar S; Leongamornlert D; Tymrakiewicz M; Saunders E; Page E; Mitra A; Mitchell G; Lindeman GJ; Evans DG; Blanco I; Mercer C; Rubinstein WS; Clowes V; Douglas F; Hodgson S; Walker L; Donaldson A; Izatt L; Dorkins H; Male A; Tucker K; Stapleton A; Lam J; Kirk J; Lilja H; Easton D; ; ; ; Cooper C; Eeles R; Neal DE
PLoS One; 2010 Oct; 5(10):e13363. PubMed ID: 20967219
[TBL] [Abstract][Full Text] [Related]
58. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
59. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
60. Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
Hormaechea-Agulla D; Gómez-Gómez E; Ibáñez-Costa A; Carrasco-Valiente J; Rivero-Cortés E; L-López F; Pedraza-Arevalo S; Valero-Rosa J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Gahete MD; López-Miranda J; Requena MJ; Castaño JP; Luque RM
Cancer Lett; 2016 Dec; 383(1):125-134. PubMed ID: 27693462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
